Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) announced Thursday that its joint-disease drug Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been added to public drug plans in four Canadian provinces.
The drug has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP), and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA).
Also for public reimbursement, TH has been approved for inclusion on the Ontario Drug Benefit Formulary/Comparative Drug Index and the Non-Insured Health Benefits – Drug Benefit List for its full Health Canada-approved indication, which includes approved use in both adults and adolescents.
TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products, the company said.
“The inclusion of our TH on these public drug plan formularies in Canada enhances the accessibility of this therapy for pediatric and adult patients suffering from chronic inflammatory diseases including JIA and RA (rheumatoid arthritis),” said Ken d’Entremont, Medexus CEO, in a statement.
“Previously, both younger and adult patients with subacute and chronic inflammatory joint diseases have had difficulty getting TH due to a long-standing shortage of Triamcinolone Hexacetonide in Canada.”
He also noted that the company is advancing the commercial rollout of TH in additional provinces.
“Moreover, we believe our formulation has the potential to become the standard of care for the treatment of many severe joint diseases, as it significantly impacts the safety and cost-effectiveness of treatment by providing longer duration of action, with fewer injections, compared to other corticosteroid injections and intra-articular steroids,” d’Entremont added.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham